Kailera Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity. Its product candidate includes Ribupatide. The company was founded on May 08, 2024 and is headquartered in Waltham, MA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
145
Frequently Asked Questions
What is Market Cap of Kailera Therapeutics Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Kailera Therapeutics Inc. market cap is $2.2B.
What is the 52-week high for Kailera Therapeutics Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Kailera Therapeutics Inc. 52 week high is $27.50 as of April 19, 2026.
What is the 52-week low for Kailera Therapeutics Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Kailera Therapeutics Inc. 52 week low is $16.00 as of April 19, 2026.
What is Kailera Therapeutics Inc. stock price today?
Kailera Therapeutics Inc. stock price today is $26.00.
What was Kailera Therapeutics Inc. stock price yesterday?
Kailera Therapeutics Inc. stock price yesterday was $16.00.
What is the 50-day moving average of Kailera Therapeutics Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Kailera Therapeutics Inc. 50-day moving average is $21.00.
How many employees does Kailera Therapeutics Inc. have?